Olema to Present Phase 1 OP-3136 Data and OPERA-02 Poster at ASCO
Olema Oncology will present initial Phase 1 data for OP-3136, a selective oral KAT6A/B inhibitor, at the ASCO Annual Meeting on May 30. The company will also unveil a trial-in-progress poster for its Phase 3 OPERA-02 palazestrant plus ribociclib study on June 1.
1. ASCO Presentation Schedule
Olema will present OP-3136 Phase 1 results on May 30 (Poster #225, 1:30–4:30pm CT) and the Phase 3 OPERA-02 trial protocol (Poster #261b) on June 1 from 1:30–4:30pm CT during the ASCO Annual Meeting in Chicago.
2. OP-3136 Phase 1 Study Details
OP-3136 is a novel oral selective KAT6A/B inhibitor evaluated as monotherapy in advanced solid tumors and combined with endocrine therapy in ER+, HER2− breast cancer. The Phase 1 poster will detail safety, tolerability and preliminary efficacy findings in its first-in-human study.
3. OPERA-02 Phase 3 Trial Overview
OPERA-02 investigates palazestrant plus ribociclib as first-line treatment for ER+, HER2− advanced breast cancer. The trial-in-progress poster will outline the randomized design, primary endpoints and patient enrollment criteria.
4. Implications for Olema Oncology
Initial OP-3136 data and OPERA-02 trial progress will inform Olema’s clinical development timeline and may enhance the company’s pipeline valuation and strategic positioning in endocrine-driven breast cancer therapies.